Aurobindo Pharma said that it received final approval from US FDA for two ANDAs namely Cefotaxime for injection USP 500 mg, 1 g, 2 g and Cefotaxime for injection USP of 10g pharmacy bulk pack.
Cefotaxime injection is generic equivalent to Claforan injection of Sanofi Aventis U. S. LLC. Cefotaxime injection falls under the anti-betallactum segment and is ready for launch.
For comments and feedback: editorial@rttnews.com